<DOC>
	<DOCNO>NCT01636414</DOCNO>
	<brief_summary>It widely report large percentage total joint replacement patient receive allogeneic ( human donor blood ) blood transfusion due perioperative blood loss number range 30 % 80 % . The risk allogenic blood transfusion well documented literature . In addition , time-consuming : often lengthen hospital stay decrease availability postoperative physical therapy . Moreover , costly several hundred dollar per unit , allogeneic transfusion link immunosuppression increase postoperative infection rate wound heal problem , devastate complication elective , joint replacement population . Several option available diminish need allogenic blood transfusion follow elective total joint replacement . These include use perioperative blood salvage device ( OrthoPAT ) tranexamic acid . While data support use OrthoPat Tranexamic acid primary total joint arthroplasty , little information compare one versus term efficacy economics . The purpose study compare safety , effectiveness cost benefit Hemovac drain , OrthoPAT Tranexamic Acid manage blood loss total hip total knee replacement surgery .</brief_summary>
	<brief_title>Reinfusion Drains vs Tranexamic Acid Total Joint Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1 . Patients present primary unilateral hip knee arthroplasty 2 . &gt; 18 year age 3 . Preoperative hemoglobin day surgery &gt; 10mg/dL 1 . Patients preoperative Hgb &lt; 10mg/dL 2 . Patients unwilling consent blood transfusion 3 . Patients history bleed disorder 4 . Patients anticoagulation therapy preoperatively ( ASA 325mg , Plavix Coumadin ) 5 . Patients history Thromboembolic event ( DVT , PE , CVA MI ) 6 . Patients platelet count &lt; 100,000 7 . Patients kidney disease ( Serum Cr &gt; 1.2 ) 8 . Patients end stage renal disease hemodialysis 9 . Patients renal transplant 10 . Patients present bilateral total hip knee arthroplasty 11 . Patients present conversion revision total hip knee procedures 12 . Patients donate preautologous blood 13 . Patients primary hematologic disease malignancy 14 . Patients allergy Tranexamic Acid 15 . Patients hepatic disease 16 . Patients discontinue steroid use prior surgery 17 . Patients religious beliefs/practices prohibit blood transfusion 18 . Patients cognitive impairment 19 . Patients terminally ill</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Total joint arthroplasty , blood loss</keyword>
</DOC>